Liana, diagnosed with hATTR amyloidosis
and her daughter Gabriella (Brazil)

Our Company

OUR PATIENT ACCESS PHILOSOPHY

Our Role in the Patient's Journey to Innovative Therapeutic Options

At Alnylam, we believe that discovery and development is only the first step in delivering the promise of RNAi therapeutics to as many patients as possible. At the core of this belief is our Patient Access Philosophy, which guides our role in access, affordability and outcomes as they relate to the value our therapies bring to the patient communities and therapeutic areas we serve.

Our Patient Access Philosophy was established in 2017, before our first medicine was even approved, and will hold us accountable through the continuous evolution that will endure for as long as we are Alnylam.

At Alnylam, we know that medical and scientific innovation are only worthwhile if the people who can benefit from life-changing therapies have access to them. Despite living in an age of medicinal breakthroughs, patients are too often unable to receive the treatment they need due to their location, their insurance, or other obstacles. We believe it is our responsibility to work with partners around the world to ensure our drugs are accessible and affordable to all, because no patient should have to wait for hope. — Yvonne Greenstreet, MBChB, CEO of Alnylam

Our Patient Access Philosophy & Progress
Fact Sheet

Download our 2023 Patient Access Philosophy Fact Sheet to see statistics that illustrate our progress against these principles.

DOWNLOAD PDF

patients on our commercial therapies worldwide

U.S. residents with confirmed access to one of our therapies

countries where patients can access our therapies by way of direct or distributor infrastructure

Alnylam’s Patient Access Philosophy Principles

Sustainable Value and Significant Impact

We believe it is our responsibility to push the boundaries of scientific discovery, clinical development, and delivery to fuel significant, sustainable patient impact.

We make decisions for as many people who can benefit from the potential of our medicines.
We believe we have an obligation to commit resources that promote diversity of clinical trials, ensure equitable access, and empower individuals with choice.

We act with purposeful urgency to expand our geographic reach and enable sustainable access pathways.

Connecting to Achieve Better Outcomes

We believe that together with partners in the healthcare ecosystem, we can reduce barriers to our medicines to improve outcomes for all stakeholders in the patient journey – most importantly, for the patients who may benefit from them.

We believe biopharmaceutical companies must address access and improve outcomes from the time of drug discovery.
We recognize that a patient’s ability to access and afford our medicines is complex, and we commit to continuing our legacy of value-centric solutions.

We seek to remove barriers within our control to enable patients to receive care in convenient settings.

Proactive and Accountable

We believe that biopharmaceutical companies play a critical role in the patient’s journey to accessing innovative therapeutic options and should be accountable for progress.

We aim to create compliant solutions that are designed to empower patients to feel confident throughout their treatment journey.
We advocate for policies, technology and evidence to promote innovation and reduce the time for approved treatments to reach patients.

We partner with others for the sake of science and the good of patients, committed to the continuous evolution that began before we launched the world’s first RNAi therapeutic and will endure for as long as we are Alnylam.

Learn More About How We Measure Our Progress Against Our Patient Access Philosophy Principles:

2023 Approach to Access and Affordability Fact Sheet

DOWNLOAD

(Format: PDF)

Corporate Social Responsibility Report 2022

DOWNLOAD

(Format: PDF)

Additional Information

Alnylam Assist®

Alnylam Assist® offers you a number of personalized services throughout your treatment with an Alnylam product.

VISIT SITE ›

Alnylam Act®

Alnylam Act® provides no-charge, independent genetic testing and counseling to individuals in the U.S. and Canada who may have hATTR amyloidosis, acute hepatic porphyria, or primary hyperoxaluria type 1.

VISIT SITE ›

SIGN UP FOR EMAIL UPDATES

Receive news and updates on the work at Alnylam that affects you most.

Sign Up Now ›